Every night, the online Belgian patent register ('eRegister') receives an update with public data that were entered or generated the preceding day on the Benelux Patent Platform, the computer application with which the Belgian Intellectual Property Office handles the registration, treatment and publication processes for patents and supplementary protection certificates.
Currently, some updates are spread over consecutive nights due to the large, weekly volume of data concerning European patents designating Belgium.
For a European patent it is possible that data about the inventor(s) are missing from the online Belgian patent register. They can be found via the link to the European patent register pending an update of the Belgian patent register.
For European patents with Unitary Effect, the authentic source of information is the European Patent Register : please refer to it.

Patent details

2021C560 Product name: Neisseria meningitidis-groep A polysacharide, Neisseria meningitidis-groep C polysacharide, Neisseria meningitidis-groep W-135 polysacharide, Neisseria meningitidis-groep Y polysacharide, geconjugeerd aan tetanustoxoïddragereiwit

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic information

Application number:
2021C/560
Type:
Certificate
SPC type:
Medical
Basic patent number:
151893971
Status:
Inactive
Publication number:
2021C560
1rst applicant's nationality:
Procedural language:
Dutch

Paediatric extension

SPC Extension filing date:
11/09/2023
SPC Extension agent/owner name:
GEVERS PATENTS
SPC Extension status:
Granted
SPC Extension grant date:
02/02/2026
SPC Extension Rejection Date:

Marketing authorization

Marketing authorization number:
EU/1/12/767
Marketing authorization type:
National/EU
Designates country:
No
Marketing authorization date:
25/04/2012
Marketing authorization status:
Accepted
Marketing authorization country:
Belgium (BE)

Dates

Filing date:
20/12/2021
First marketing authorization date:
25/04/2012
Grant date:
02/02/2026
Activation date:
BE Publication date:
04/01/2022
Lapsed date:
Expiration date (if granted and all annual fees paid):
Basic SPC Expiration (if granted and all annual fees paid):
25/04/2027
SPC/SPC Extension Expiration (if granted and all annual fees paid):
25/10/2027
Rejection date:
Withdrawal date:

Applicant

Name:
Pfizer Ireland Pharmaceuticals
Legal Form:
Private Unlimited With Share Capital
From:
04/01/2022
Address:
Operations Support Group, Ringaskiddy Cork, Ireland (IE)
To:

Agent

1

Name:
GEVERS PATENTS
Legal Form:
From:
08/02/2024
Address:
De Kleetlaan 7A, 1831, DIEGEM, Belgium (BE)
To:

2

Name:
GEVERS PATENTS
Legal Form:
From:
21/12/2021
Address:
Holidaystraat 5, 1831, DIEGEM, Belgium (BE)
To:
08/02/2024

Publication

Bulletin

1

Bulletin heading:
SPC
Journal edition number:
2022/01
Publication date:
09/02/2022
Description:
Contains data concerning applications for- or granted Supplementary Protection Certificates

2

Bulletin heading:
SPC
Journal edition number:
2023/17
Publication date:
03/10/2023
Description:
Contains data concerning applications for- or granted Supplementary Protection Certificates

3

Bulletin heading:
SPC
Journal edition number:
2026/03
Publication date:
26/02/2026
Description:
Contains data concerning applications for- or granted Supplementary Protection Certificates

4

Bulletin heading:
SPC
Journal edition number:
2026/03
Publication date:
26/02/2026
Description:
Contains data concerning applications for- or granted Supplementary Protection Certificates

Annual fee

Annual fee(s) Due Date:
Annual fee number:
Expected payer:
Last annual fee payment date:
24/03/2026
Last annual fee paid number:
21
Last annual fee paid amount:
650 Euro
Payer:
CLARIVATE ANALYTICS (MASTER DATA CENTER)
Filing date Document type Publication Type Document Description Number of pages File Type
20/12/2021 Abstract Product Characteristics Abstract of the characteristics of the product 55 PDF /0/0/5/8/8/0722188500/docs/2021c560_0_abstractproductcharacteristics_20211221_084624454.pdf
20/12/2021 MA Official Publication Official Publication of 1st Marketing Authorization 11 PDF /0/0/5/8/8/0722188500/docs/2021c560_1_maofficialpublication_20211221_084625025.pdf
20/12/2021 General Document Other 2 PDF /0/0/5/8/8/0722188500/docs/2021c560_2_generaldocument_20211221_084624101.pdf
20/12/2021 Marketing Authorization 1st Marketing Authorization (EU) 5 PDF /0/0/5/8/8/0722188500/docs/2021c560_3_marketingauthorization_20211221_084625289.pdf
08/02/2024 Request For Change Letter and/or Form requesting a change in the Register 2 PDF /0/0/5/8/8/0722188500/docs/2021c560_4_rfc_20240425_085642791.pdf
11/09/2023 Paediatric Investigation Plan Paediatric Investigation Plan (PIP) 1 PDF /0/0/5/8/8/0722188500/docs/2021c560_5_paediatricinvestigationplan_20230912_084553382.pdf
11/09/2023 General Document Other 85 PDF /0/0/5/8/8/0722188500/docs/2021c560_6_generaldocument_20230912_084553734.pdf
11/09/2023 General Document Other 1 PDF /0/0/5/8/8/0722188500/docs/2021c560_7_generaldocument_20230912_084553612.pdf
11/09/2023 Marketing Authorization 1st Paediatric Marketing Authorization (EU) 3 PDF /0/0/5/8/8/0722188500/docs/2021c560_8_marketingauthorization_20230912_084555201.pdf
11/09/2023 Application Form 3 PDF /0/0/5/8/8/0722188500/docs/2021c560_9_applicationform_20230912_084555470.pdf
12/09/2023 Outgoing Correspondence 2 PDF /0/0/5/8/8/0722188500/docs/2021c560_10_outgoingcorrespondence_20230925_115453450.pdf
04/01/2022 Outgoing Correspondence 2 PDF /0/0/5/8/8/0722188500/docs/2021c560_11_outgoingcorrespondence_20220117_104810828.pdf
20/12/2021 Application Form 4 PDF /0/0/5/8/8/0722188500/docs/2021c560_12_applicationform_20211221_084625495.pdf
02/02/2026 Certificate 2 PDF /0/0/5/8/8/0722188500/docs/2021c560_13_spc_xcertificate_20260202_234049598.pdf
04/01/2022 Publication I1 1 PDF /0/0/5/8/8/0722188500/docs/2021c560_14_i1document_20220104_125137663.pdf
02/02/2026 Publication I2 1 PDF /0/0/5/8/8/0722188500/docs/2021c560_15_i2document_20260202_231836099.pdf
12/09/2023 Publication I1E 1 PDF /0/0/5/8/8/0722188500/docs/2021c560_16_i1edocument_20230912_112301075.pdf
02/02/2026 Publication I2E 1 PDF /0/0/5/8/8/0722188500/docs/2021c560_17_i2edocument_20260202_234049418.pdf
02/02/2026 Outgoing Correspondence 2 PDF /0/0/5/8/8/0722188500/docs/2021c560_18_outgoingcorrespondence_20260216_024918481.pdf
02/02/2026 Outgoing Correspondence 2 PDF /0/0/5/8/8/0722188500/docs/2021c560_19_outgoingcorrespondence_20260216_024813362.pdf